Enabling Scalable Gene Editing with Nanoplasmid^TM DNA

August 26, 2026 by Tyler Kozisek

Fixing the DNA Payload Problem

As non-viral delivery systems advance, the DNA payload itself has become a central bottleneck. Traditional plasmids carry bacterial elements that reduce expression efficiency, increase immunogenicity, and complicate translation to clinical settings. This is where Nanoplasmid^TM DNA emerges as a critical enabling technology.

Why DNA Format Matters More Than Ever
At the ASGCT Annual Meeting, multiple talks highlighted a recurring issue—standard plasmids such as pUC backbones are still widely used in early studies, but performance limitations become apparent when translating to larger payloads, in vivo systems, and clinical settings.

There was explicit recognition that:

• Removing bacterial backbone sequences improves performance
• Smaller, cleaner DNA constructs enhance integration and expression

Impact on Integration Efficiency and Expression
Key observations aligned with Nanoplasmid advantages:

• Improved knock-in (KI) efficiency with optimized DNA formats
• Challenges with multi-gene expression when using standard plasmids
• Better performance for large constructs when DNA design is optimized

In systems exploring dual CAR constructs (e.g., CD19 + CD20), or multi-gene payloads with 2A elements, DNA architecture significantly influenced expression balance and durability.

Compatibility with Emerging Editing Platforms
Nanoplasmid is particularly well-aligned with next-generation systems:

• CRISPR/HDR-based integration
• Serine integrase-mediated insertion
• Large cargo gene writing systems
• LNP-mediated in vivo delivery

In these contexts, DNA payload needs to be compact, must avoid triggering innate immunity and must support precise integration, all hallmarks of Nanoplasmid DNA.

Manufacturing and Cost Considerations
A notable theme from discussions. Some groups explicitly cited cost barriers preventing adoption of optimized DNA formats, highlighting a key inflection point: Performance advantages are clear—but adoption depends on making them accessible.

Nanoplasmid DNA addresses this by:

• Enabling scalable GMP-compatible production
• Reducing complexity compared to viral systems
• Supporting multi-indication use

Strategic Positioning
From a BD perspective, the DNA backbone is no longer a passive component—it is an active driver of therapeutic performance. Nanoplasmid DNA enables:

• Higher editing efficiency
• More consistent expression
• Better compatibility with advanced gene editing systems

The Takeaway: Unlocking Next-Generation Payloads
As gene therapies move toward larger constructs, multi-functional payloads and in vivo editing the industry will require DNA platforms purpose-built for performance. Nanoplasmid DNA stands out as a foundational technology enabling this transition, bridging the gap between experimental systems and real-world therapeutics.

• Have questions on this topic? Contact Us
• Find out more about Nanoplasmids
• Have an idea for a topic? Let us know!

Still on the fence on if the Nanoplasmid is right for your nonviral gene delivery application? Try one of Aldevron’s free off the shelf Nanoplasmid reporters, offered with EGFP or firefly luciferase to meet your in-house assay needs.

Subscribe to our blog